Shereen Hamdi Noshi <br/><br/>
Gastroretentive system for delivering an antipsychotic drug /  
 نظام لإستبقاء الأدوية المضادة للذهان فى المعدة 
Shereen Hamdi Noshi ; Supervised Mahmoud M. Ghorab , Hussein O. Ammar 
 - Cairo :   Shereen Hamdi Noshi ,   2015 
 - 244 P. :   charts , facsimiles ;   25cm 
<br/><br/>Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics 
<br/><br/> Schizophrenia is a severe and disabling mental illness. It affects approximately 1% of the population worldwide and it is a chronic, severe  disorder, lacking curative treatment. The suicide rate is as high as 9 - 13%, with the incidence of suicide attempt reaching 50% of diagnosed patients over a lifetime. The onset of schizophrenia usually occurs around 18 -  25 years of age and is often preceded by premorbid behavioural deviations, such as social withdrawal and affective changes. The symptoms and severity can vary over individual with schizophrenia. The symptoms are commonly divided into three  categories, namely, positive symptoms, negative symptoms and cognitive deficits. Antipsychotics can be broadly classified into first generation  antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known as atypical antipsychotics). First - generation antipsychotics are as effective as second - generation drugs in treating the 2positive3 symptoms of schizophrenia, such as hallucinations, delusions, and paranoia, although they vary in  their propensity to cause side effects 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Antipsychotic drug Gastroretentive system Pharmaceutics